Anti-RNF133 monoclonal antibody

Pre-made anti-RNF133 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to RNF133/RNF133 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1507-Ab-1/ GM-Tg-hg-IP1507-Ab-2Anti-Human RNF133 monoclonal antibodyHuman
GM-Tg-rg-IP1507-Ab-1/ GM-Tg-rg-IP1507-Ab-2Anti-Rat RNF133 monoclonal antibodyRat
GM-Tg-mg-IP1507-Ab-1/ GM-Tg-mg-IP1507-Ab-2Anti-Mouse RNF133 monoclonal antibodyMouse
GM-Tg-cynog-IP1507-Ab-1/ GM-Tg-cynog-IP1507-Ab-2Anti-Cynomolgus/ Rhesus macaque RNF133 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1507-Ab-1/ GM-Tg-felg-IP1507-Ab-2Anti-Feline RNF133 monoclonal antibodyFeline
GM-Tg-cang-IP1507-Ab-1/ GM-Tg-cang-IP1507-Ab-2Anti-Canine RNF133 monoclonal antibodyCanine
GM-Tg-bovg-IP1507-Ab-1/ GM-Tg-bovg-IP1507-Ab-2Anti-Bovine RNF133 monoclonal antibodyBovine
GM-Tg-equg-IP1507-Ab-1/ GM-Tg-equg-IP1507-Ab-2Anti-Equine RNF133 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1507-Ab-1/ GM-Tg-hg-IP1507-Ab-2; GM-Tg-rg-IP1507-Ab-1/ GM-Tg-rg-IP1507-Ab-2;
GM-Tg-mg-IP1507-Ab-1/ GM-Tg-mg-IP1507-Ab-2; GM-Tg-cynog-IP1507-Ab-1/ GM-Tg-cynog-IP1507-Ab-2;
GM-Tg-felg-IP1507-Ab-1/ GM-Tg-felg-IP1507-Ab-2; GM-Tg-cang-IP1507-Ab-1/ GM-Tg-cang-IP1507-Ab-2;
GM-Tg-bovg-IP1507-Ab-1/ GM-Tg-bovg-IP1507-Ab-2; GM-Tg-equg-IP1507-Ab-1/ GM-Tg-equg-IP1507-Ab-2
Products NameAnti-RNF133 monoclonal antibody
Formatmab
Target NameRNF133
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-RNF133 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1507-Ag-1Recombinant multi-species RN133/ RNF133 protein


    Target information

    Target IDGM-IP1507
    Target NameRNF133
    Gene ID168433,386611,681395,694972,102152555,102901069,101906117,102149188
    Gene Symbol and SynonymsGreul2,RNF133
    Uniprot AccessionQ8WVZ7,Q6AY01
    Uniprot Entry NameRN133_HUMAN,RN133_RAT
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000188050
    Target ClassificationN/A

    The target: RNF133, gene name: RNF133, also named as . The protein encoded by this gene contains a RING finger domain, a motif present in a variety of functionally distinct proteins and known to be involved in protein-protein and protein-DNA interactions. This gene has no intron. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.